SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 12, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed3d 18h ago
Insider cluster: 2 insiders, $139K total
Actionable Insight • Neutral

The sales are trivial in size relative to market cap and involve the General Counsel and a non-C-suite insider. No material bearish signal. Monitor next insider cluster for larger dollar amounts or C-suite participation.

DirectionNeutral
Confidencehigh
Horizonimmediate

Drugs in focus

RCKT drug pipeline →

KRESLADI

● Neutral Named in this insider cluster
Impact
Phase
Approved (FDA accelerated approval)
Time to market
Already FDA-approved (March 26, 2026); commercial launch underway
Next catalyst
None dated

What to watchKRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$2.30
T+0 close · Nov 12, 2026 · via day close
Latest settled
−6.09%
T+1 · $2.16
Vs SPY
−4.18%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $2.30entry
  2. T+1 · 20h ago −6.09%α −4.18% · $2.16
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders at Rocket Pharmaceuticals sold a combined $139K in open-market sales within days of the Q3 2026 earnings release. The sales are small relative to the $272M market cap (0.05%) and are not under 10b5-1 plans, but the dollar amount is below the materiality threshold for a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$139.0K
Insiders
2

Key Facts

  • General Counsel sold 53.4K shares at $2.39 for $128K on 2026-11-05 (open-market, no 10b5-1 plan)
  • See Remarks insider sold 4.9K shares at $2.33 for $11K on 2026-11-09 (open-market, no 10b5-1 plan)
  • Total open-market sales: $139K, representing 0.05% of $272M market cap
  • Sales occurred 1-7 days before the Q3 2026 earnings release on 2026-11-12
  • Q3 2026 earnings reported cash of $279.4M, commercial readiness for KRESLADI, and FDA alignment on Danon disease pivotal trial

Financial Impact

Total insider sales of $139K, well under 0.1% of market cap

insider ownership

Risk Factors

  • Small insider sales could be for personal liquidity; no 10b5-1 plan disclosed
  • No C-suite (CEO/CFO) selling, reducing signal strength

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RCKT-1794527071727

Track record

21 reports on RCKT

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  3. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Viewing Entry $2.30 Now $2.16 −6.09% settles Dec 14
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
  5. Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
  7. Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
  8. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
  9. Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
  10. Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026